Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays
In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-C...
Uložené v:
| Vydané v: | Molecular & cellular proteomics Ročník 22; číslo 4; s. 100507 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Elsevier Inc
01.04.2023
THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology |
| Predmet: | |
| ISSN: | 1535-9476, 1535-9484, 1535-9484 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-CoV-2 variant protein microarray that contained the spike proteins from the VOCs, e.g., alpha, beta, gamma, delta, and omicron, to quantify the binding antibody and surrogate neutralizing antibody. Plasmas were collected after two doses of matching AZD1222 (AZx2), two doses of matching mRNA-1273 (Mx2), or mixing AZD1222 and mRNA-1273 (AZ+M). The results showed a significant decrease of surrogate neutralizing antibodies against the receptor-binding domain in all VOCs in AZx2 and Mx2 but not AZ+M. A similar but minor reduction pattern of surrogate neutralizing antibodies against the extracellular domain was observed. While Mx2 exhibited a higher surrogate neutralizing level against all VOCs compared with AZx2, AZ+M showed an even higher surrogate neutralizing level in gamma and omicron compared with Mx2. It is worth noting that the binding antibody displayed a low correlation to the surrogate neutralizing antibody (R-square 0.130–0.382). This study delivers insights into humoral immunities, SARS-CoV-2 mutations, and mixing and matching vaccine strategies, which may provide a more effective vaccine strategy especially in preventing omicron.
[Display omitted]
•Establish CoVariant protein arrays including spike proteins from wild-type to omicron variants.•Concurrently detect neutralizing and binding antibodies against multiple SARS-CoV-2 variants.•Mixing of AZD1222 and mRNA-1273 generates better humoral immunity against omicron than matching.
Owing to the ongoing mutations of SARS-CoV-2, we developed an up-to-date CoVariant protein microarray to profile the humoral immunity. We collected plasmas from healthy subjects who underwent two doses of matching (AZD1222 ×2 or mRNA-1273 ×2) and two doses of mixing (AZD1222 + mRNA-1273). We found that mixing generates more surrogate neutralizing activity against gamma and omicron than matching. This study not only provides a high-throughput tool but also delivers a vaccine strategy to fight against SARS-CoV-2 mutations. |
|---|---|
| AbstractList | In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-CoV-2 variant protein microarray that contained the spike proteins from the VOCs, e.g., alpha, beta, gamma, delta, and omicron, to quantify the binding antibody and surrogate neutralizing antibody. Plasmas were collected after two doses of matching AZD1222 (AZx2), two doses of matching mRNA-1273 (Mx2), or mixing AZD1222 and mRNA-1273 (AZ+M). The results showed a significant decrease of surrogate neutralizing antibodies against the receptor-binding domain in all VOCs in AZx2 and Mx2 but not AZ+M. A similar but minor reduction pattern of surrogate neutralizing antibodies against the extracellular domain was observed. While Mx2 exhibited a higher surrogate neutralizing level against all VOCs compared with AZx2, AZ+M showed an even higher surrogate neutralizing level in gamma and omicron compared with Mx2. It is worth noting that the binding antibody displayed a low correlation to the surrogate neutralizing antibody (R-square 0.130-0.382). This study delivers insights into humoral immunities, SARS-CoV-2 mutations, and mixing and matching vaccine strategies, which may provide a more effective vaccine strategy especially in preventing omicron. In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Due to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-CoV-2 variant protein microarray that contained the spike proteins from the VOCs, e.g., alpha, beta, gamma, delta, and omicron, to quantify the binding antibody and surrogate neutralizing antibody. Plasmas were collected after two doses of matching AZD1222 (AZx2), two doses of matching mRNA-1273 (Mx2), or mixing AZD1222 and mRNA-1273 (AZ+M). The results showed a significant decrease of surrogate neutralizing antibodies against the receptor-binding domain in all VOCs in AZx2 and Mx2 but not AZ+M. A similar but minor reduction pattern of surrogate neutralizing antibodies against the extracellular domain was observed. While Mx2 exhibited a higher surrogate neutralizing level against all VOCs compared to AZx2, AZ+M showed an even higher surrogate neutralizing level in gamma and omicron compared to Mx2. It is worth noting that the binding antibody displayed a low correlation to the surrogate neutralizing antibody (R-square 0.130-0.382). This study delivers insights into humoral immunities, SARS-CoV-2 mutations, and mixing and matching vaccine strategies, which may provide a more effective vaccine strategy especially in preventing omicron. In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-CoV-2 variant protein microarray that contained the spike proteins from the VOCs, e.g., alpha, beta, gamma, delta, and omicron, to quantify the binding antibody and surrogate neutralizing antibody. Plasmas were collected after two doses of matching AZD1222 (AZx2), two doses of matching mRNA-1273 (Mx2), or mixing AZD1222 and mRNA-1273 (AZ+M). The results showed a significant decrease of surrogate neutralizing antibodies against the receptor-binding domain in all VOCs in AZx2 and Mx2 but not AZ+M. A similar but minor reduction pattern of surrogate neutralizing antibodies against the extracellular domain was observed. While Mx2 exhibited a higher surrogate neutralizing level against all VOCs compared with AZx2, AZ+M showed an even higher surrogate neutralizing level in gamma and omicron compared with Mx2. It is worth noting that the binding antibody displayed a low correlation to the surrogate neutralizing antibody (R-square 0.130-0.382). This study delivers insights into humoral immunities, SARS-CoV-2 mutations, and mixing and matching vaccine strategies, which may provide a more effective vaccine strategy especially in preventing omicron.In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-CoV-2 variant protein microarray that contained the spike proteins from the VOCs, e.g., alpha, beta, gamma, delta, and omicron, to quantify the binding antibody and surrogate neutralizing antibody. Plasmas were collected after two doses of matching AZD1222 (AZx2), two doses of matching mRNA-1273 (Mx2), or mixing AZD1222 and mRNA-1273 (AZ+M). The results showed a significant decrease of surrogate neutralizing antibodies against the receptor-binding domain in all VOCs in AZx2 and Mx2 but not AZ+M. A similar but minor reduction pattern of surrogate neutralizing antibodies against the extracellular domain was observed. While Mx2 exhibited a higher surrogate neutralizing level against all VOCs compared with AZx2, AZ+M showed an even higher surrogate neutralizing level in gamma and omicron compared with Mx2. It is worth noting that the binding antibody displayed a low correlation to the surrogate neutralizing antibody (R-square 0.130-0.382). This study delivers insights into humoral immunities, SARS-CoV-2 mutations, and mixing and matching vaccine strategies, which may provide a more effective vaccine strategy especially in preventing omicron. In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern (VOCs), it is important to monitor the humoral immune responses after different vaccination strategies. In this study, we developed a SARS-CoV-2 variant protein microarray that contained the spike proteins from the VOCs, e.g., alpha, beta, gamma, delta, and omicron, to quantify the binding antibody and surrogate neutralizing antibody. Plasmas were collected after two doses of matching AZD1222 (AZx2), two doses of matching mRNA-1273 (Mx2), or mixing AZD1222 and mRNA-1273 (AZ+M). The results showed a significant decrease of surrogate neutralizing antibodies against the receptor-binding domain in all VOCs in AZx2 and Mx2 but not AZ+M. A similar but minor reduction pattern of surrogate neutralizing antibodies against the extracellular domain was observed. While Mx2 exhibited a higher surrogate neutralizing level against all VOCs compared with AZx2, AZ+M showed an even higher surrogate neutralizing level in gamma and omicron compared with Mx2. It is worth noting that the binding antibody displayed a low correlation to the surrogate neutralizing antibody (R-square 0.130–0.382). This study delivers insights into humoral immunities, SARS-CoV-2 mutations, and mixing and matching vaccine strategies, which may provide a more effective vaccine strategy especially in preventing omicron. [Display omitted] •Establish CoVariant protein arrays including spike proteins from wild-type to omicron variants.•Concurrently detect neutralizing and binding antibodies against multiple SARS-CoV-2 variants.•Mixing of AZD1222 and mRNA-1273 generates better humoral immunity against omicron than matching. Owing to the ongoing mutations of SARS-CoV-2, we developed an up-to-date CoVariant protein microarray to profile the humoral immunity. We collected plasmas from healthy subjects who underwent two doses of matching (AZD1222 ×2 or mRNA-1273 ×2) and two doses of mixing (AZD1222 + mRNA-1273). We found that mixing generates more surrogate neutralizing activity against gamma and omicron than matching. This study not only provides a high-throughput tool but also delivers a vaccine strategy to fight against SARS-CoV-2 mutations. |
| ArticleNumber | 100507 |
| Author | Kuo, Kuang-Che Du, Pin-Xian Kuo, Ho-Chang Su, Wen-Yu Pau, Chi Ho Tsai, Pei-Shan Syu, Guan-Da Keskin, Batuhan Birol Shih, Hsi-Chang Ho, Tzong-Shiann Weng, Ken-Pen Huang, Ying-Hsien |
| Author_xml | – sequence: 1 givenname: Ho-Chang surname: Kuo fullname: Kuo, Ho-Chang organization: Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan – sequence: 2 givenname: Kuang-Che surname: Kuo fullname: Kuo, Kuang-Che organization: Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan – sequence: 3 givenname: Pin-Xian surname: Du fullname: Du, Pin-Xian organization: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan – sequence: 4 givenname: Batuhan Birol surname: Keskin fullname: Keskin, Batuhan Birol organization: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan – sequence: 5 givenname: Wen-Yu surname: Su fullname: Su, Wen-Yu organization: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan – sequence: 6 givenname: Tzong-Shiann surname: Ho fullname: Ho, Tzong-Shiann organization: Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan – sequence: 7 givenname: Pei-Shan surname: Tsai fullname: Tsai, Pei-Shan organization: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan – sequence: 8 givenname: Chi Ho surname: Pau fullname: Pau, Chi Ho organization: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan – sequence: 9 givenname: Hsi-Chang surname: Shih fullname: Shih, Hsi-Chang organization: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 10 givenname: Ying-Hsien surname: Huang fullname: Huang, Ying-Hsien organization: Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan – sequence: 11 givenname: Ken-Pen orcidid: 0000-0002-0649-1803 surname: Weng fullname: Weng, Ken-Pen organization: Congenital Structural Heart Disease Center, Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan – sequence: 12 givenname: Guan-Da orcidid: 0000-0003-4661-414X surname: Syu fullname: Syu, Guan-Da email: guanda@gs.ncku.edu.tw organization: Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36787877$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UUtv1DAYtFARfcAvQEI5csniR2wnB5BWC7QrtSqidK-W1_nSepXYW9up2H9fh20r4FD5YH-PmZFnjtGB8w4Qek_wjGAiPm1mg9kGP6OYstzBHMtX6IhwxsumqquD57cUh-g4xg3GFBPJ36BDJmSdjzxC8Ufwne2tuynOxsEH3RfLYRidTbti3iUIxYX9PU21a4sLncztVCwuV8uvJWmKlTbGOojFdZz6V_OfV-XCr0qaJ8Fql4rMn8C6TGOC1yHoXXyLXne6j_Du8T5B19-__VqcleeXp8vF_Lw0FW9SCYY1ooaWaVnztWjqak0FpUxi4JSxrmKkxV2raxAV0VgI0QDB3ZrwSrMaAztBX_a823E9QGvApfw_tQ120GGnvLbq34mzt-rG36umoZRingk-PhIEfzdCTGqw0UDfawd-jIpKKTEhHJO8-uFvrWeRJ6fzQrNfyDbEGKBTxiadrJ-kba8IVlOqaqP-pKqmVNU-1Yxl_2Gf6F9Gfd6jIHt8byGoaCw4A60NYJJqvX0R_wCTh7wQ |
| CitedBy_id | crossref_primary_10_1093_rap_rkad085 crossref_primary_10_1016_j_bios_2023_115709 crossref_primary_10_1080_07853890_2024_2442533 crossref_primary_10_1007_s44211_023_00396_4 crossref_primary_10_1080_21505594_2024_2351266 |
| Cites_doi | 10.1126/science.abn7591 10.1038/s41586-021-04120-y 10.1056/NEJMoa2101765 10.1038/s41392-022-00978-0 10.3389/fimmu.2021.744242 10.1016/j.bios.2022.114067 10.1038/s41598-022-07849-2 10.1126/scitranslmed.abn8057 10.1038/s41586-021-04389-z 10.1038/s41591-021-01464-w 10.1128/JVI.02002-17 10.1038/s41586-020-2571-7 10.1038/s41467-022-31796-1 10.1021/acs.analchem.1c05567 10.1016/j.vaccine.2015.11.062 10.1038/s41467-022-31300-9 10.1056/NEJMoa2113017 10.1126/science.abl9463 10.1038/s41591-021-01449-9 10.1016/j.cell.2021.01.037 10.1056/NEJMra2206573 10.2807/1560-7917.ES.2022.27.18.2200322 10.1016/j.jaci.2022.01.013 10.1016/j.chom.2021.03.005 10.1056/NEJMoa2118691 10.1038/s41598-020-76913-6 10.1038/d41586-021-00315-5 10.1038/s41586-021-04385-3 10.1371/journal.pone.0269032 10.1038/s41587-020-0631-z 10.1038/s42003-021-01649-6 10.1126/science.abn2688 10.1056/NEJMoa2034577 10.1056/NEJMoa2104840 10.1021/acs.analchem.1c00614 10.1016/S0140-6736(20)32661-1 10.3390/vaccines10091396 10.1016/j.coi.2009.05.016 10.1056/NEJMoa2115624 10.1016/S0140-6736(21)01420-3 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. 2023 The Authors 2023 |
| Copyright_xml | – notice: 2023 The Authors – notice: Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. – notice: 2023 The Authors 2023 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.mcpro.2023.100507 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| EISSN | 1535-9484 |
| ExternalDocumentID | PMC9922205 36787877 10_1016_j_mcpro_2023_100507 S1535947623000166 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0SF 123 18M 29M 2WC 34G 39C 4.4 53G 5VS 6I. AAEDW AAFTH AAFWJ AAXUO ABDNZ ACGFO ACIWK ACPRK ACYGS ADBBV AENEX AEXQZ AFPKN AFRAH ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BTFSW C1A CS3 DIK DU5 E3Z EBS EJD F5P FDB FRP GROUPED_DOAJ GX1 HH5 HYE KQ8 OK1 P2P RHF RHI RNS ROL RPM TBC TR2 W8F WOQ ZA5 0R~ AALRI AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AIGII AITUG AKBMS AKRWK AKYEP CITATION H13 CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c459t-ec3968ed3a785b6984b2622370e5233f431d0fda8e641a06669e10fb154a380e3 |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001003128700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1535-9476 1535-9484 |
| IngestDate | Thu Aug 21 18:38:20 EDT 2025 Thu Oct 02 11:56:46 EDT 2025 Thu Jan 02 22:52:52 EST 2025 Wed Oct 29 21:11:54 EDT 2025 Tue Nov 18 21:57:03 EST 2025 Fri Feb 23 02:37:10 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | COVID-19 ACE2 VOCs vaccine RBD protein microarray mix-and-match ECD SARS-CoV-2 variants AZ M NTD |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c459t-ec3968ed3a785b6984b2622370e5233f431d0fda8e641a06669e10fb154a380e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 First Authors |
| ORCID | 0000-0002-0649-1803 0000-0003-4661-414X |
| OpenAccessLink | http://dx.doi.org/10.1016/j.mcpro.2023.100507 |
| PMID | 36787877 |
| PQID | 2777011501 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9922205 proquest_miscellaneous_2777011501 pubmed_primary_36787877 crossref_citationtrail_10_1016_j_mcpro_2023_100507 crossref_primary_10_1016_j_mcpro_2023_100507 elsevier_sciencedirect_doi_10_1016_j_mcpro_2023_100507 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-01 |
| PublicationDateYYYYMMDD | 2023-04-01 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular & cellular proteomics |
| PublicationTitleAlternate | Mol Cell Proteomics |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology |
| Publisher_xml | – name: Elsevier Inc – name: THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology |
| References | Ledford (bib39) 2021; 590 Muik, Lui, Wallisch, Bacher, Muhl, Reinholz (bib19) 2022; 375 Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (bib1) 2021; 397 El Sahly, Baden, Essink, Doblecki-Lewis, Martin, Anderson (bib2) 2021; 385 Du, Chou, Santos, Keskin, Hsieh, Ho (bib13) 2021; 93 Hall, Foulkes, Insalata, Kirwan, Saei, Atti (bib40) 2022; 386 Cao, Wang, Jian, Xiao, Song, Yisimayi (bib24) 2022; 602 Arbel, Hammerman, Sergienko, Friger, Peretz, Netzer (bib22) 2021; 385 Evans, Zeng, Carlin, Lozanski, Saif, Oltz (bib18) 2022; 14 Barros-Martins, Hammerschmidt, Cossmann, Odak, Stankov, Morillas Ramos (bib27) 2021; 27 Cerutti, Guo, Zhou, Gorman, Lee, Rapp (bib37) 2021; 29 Su, Du, Santos, Ho, Keskin, Pau (bib12) 2022; 94 Kim, Yao, Marsh, Eckert, Kay, Lyakisheva (bib32) 2022; 13 Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (bib3) 2020; 383 Karp, Danh, Espinoza, Seftel, Robinson, Tsai (bib36) 2020; 10 Thomson, Rosen, Shepherd, Spreafico, da Silva Filipe, Wojcechowskyj (bib4) 2021; 184 Liu, Wang, Nair, Yu, Rapp, Wang (bib14) 2020; 584 Tan, Chia, Qin, Liu, Chen, Tiu (bib20) 2020; 38 Barouch (bib6) 2022; 387 Dagan, Barda, Kepten, Miron, Perchik, Katz (bib21) 2021; 384 Kardani, Bolhassani, Shahbazi (bib7) 2016; 34 Danh, Karp, Singhal, Tankasala, Gebhart, de Jesus Cortez (bib38) 2022; 13 Borobia, Carcas, Perez-Olmeda, Castano, Bertran, Garcia-Perez (bib30) 2021; 398 Wang, Shi, Chappell, Joyce, Zhang, Kanekiyo (bib35) 2018; 92 Lafon, Jager, Bauer, Reindl, Bellmann-Weiler, Wilflingseder (bib17) 2022; 149 Dogan, Kozhaya, Placek, Gunter, Yigit, Hardy (bib34) 2021; 4 Nordstrom, Ballin, Nordstrom (bib31) 2021; 11 Greinacher, Thiele, Warkentin, Weisser, Kyrle, Eichinger (bib9) 2021; 384 Pozzetto, Legros, Djebali, Barateau, Guibert, Villard (bib10) 2021; 600 Zhang, Xiao, Cai, Lavine, Peng, Zhu (bib15) 2021; 374 Kaku, Champney, Normark, Garcia, Johnson, Ahlm (bib28) 2022; 375 Sanchez-Sendra, Albert, Zulaica, Torres, Gimenez, Botija (bib16) 2022; 12 Lu (bib8) 2009; 21 Ho, Du, Su, Santos, Lin, Chou (bib11) 2022; 204 Wang, Yang, Mei, Zhou, Tang, Li (bib41) 2022; 7 Planas, Saunders, Maes, Guivel-Benhassine, Planchais, Buchrieser (bib25) 2022; 602 Cervantes-Luevano, Espino-Vazquez, Flores-Acosta, Bernaldez-Sarabia, Cabanillas-Bernal, Gasperin-Bulbarela (bib33) 2022; 17 Lou, Li, Pang, Jiang, Guan, Tian (bib5) 2021; 12 Schmidt, Klemis, Schub, Mihm, Hielscher, Marx (bib29) 2021; 27 Björk, Bonander, Moghaddassi, Rasmussen, Malmqvist, Inghammar (bib23) 2022; 27 Zhu, Liu, Zhang (bib26) 2022; 10 Danh (10.1016/j.mcpro.2023.100507_bib38) 2022; 13 Kim (10.1016/j.mcpro.2023.100507_bib32) 2022; 13 Polack (10.1016/j.mcpro.2023.100507_bib3) 2020; 383 Lou (10.1016/j.mcpro.2023.100507_bib5) 2021; 12 Barouch (10.1016/j.mcpro.2023.100507_bib6) 2022; 387 Lu (10.1016/j.mcpro.2023.100507_bib8) 2009; 21 Nordstrom (10.1016/j.mcpro.2023.100507_bib31) 2021; 11 Greinacher (10.1016/j.mcpro.2023.100507_bib9) 2021; 384 Sanchez-Sendra (10.1016/j.mcpro.2023.100507_bib16) 2022; 12 El Sahly (10.1016/j.mcpro.2023.100507_bib2) 2021; 385 Muik (10.1016/j.mcpro.2023.100507_bib19) 2022; 375 Björk (10.1016/j.mcpro.2023.100507_bib23) 2022; 27 Cervantes-Luevano (10.1016/j.mcpro.2023.100507_bib33) 2022; 17 Cao (10.1016/j.mcpro.2023.100507_bib24) 2022; 602 Barros-Martins (10.1016/j.mcpro.2023.100507_bib27) 2021; 27 Schmidt (10.1016/j.mcpro.2023.100507_bib29) 2021; 27 Kardani (10.1016/j.mcpro.2023.100507_bib7) 2016; 34 Du (10.1016/j.mcpro.2023.100507_bib13) 2021; 93 Lafon (10.1016/j.mcpro.2023.100507_bib17) 2022; 149 Borobia (10.1016/j.mcpro.2023.100507_bib30) 2021; 398 Planas (10.1016/j.mcpro.2023.100507_bib25) 2022; 602 Hall (10.1016/j.mcpro.2023.100507_bib40) 2022; 386 Wang (10.1016/j.mcpro.2023.100507_bib41) 2022; 7 Tan (10.1016/j.mcpro.2023.100507_bib20) 2020; 38 Dagan (10.1016/j.mcpro.2023.100507_bib21) 2021; 384 Wang (10.1016/j.mcpro.2023.100507_bib35) 2018; 92 Zhang (10.1016/j.mcpro.2023.100507_bib15) 2021; 374 Ledford (10.1016/j.mcpro.2023.100507_bib39) 2021; 590 Arbel (10.1016/j.mcpro.2023.100507_bib22) 2021; 385 Zhu (10.1016/j.mcpro.2023.100507_bib26) 2022; 10 Dogan (10.1016/j.mcpro.2023.100507_bib34) 2021; 4 Voysey (10.1016/j.mcpro.2023.100507_bib1) 2021; 397 Thomson (10.1016/j.mcpro.2023.100507_bib4) 2021; 184 Ho (10.1016/j.mcpro.2023.100507_bib11) 2022; 204 Pozzetto (10.1016/j.mcpro.2023.100507_bib10) 2021; 600 Su (10.1016/j.mcpro.2023.100507_bib12) 2022; 94 Cerutti (10.1016/j.mcpro.2023.100507_bib37) 2021; 29 Liu (10.1016/j.mcpro.2023.100507_bib14) 2020; 584 Karp (10.1016/j.mcpro.2023.100507_bib36) 2020; 10 Kaku (10.1016/j.mcpro.2023.100507_bib28) 2022; 375 Evans (10.1016/j.mcpro.2023.100507_bib18) 2022; 14 |
| References_xml | – volume: 602 start-page: 671 year: 2022 end-page: 675 ident: bib25 article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization publication-title: Nature – volume: 375 start-page: 678 year: 2022 end-page: 680 ident: bib19 article-title: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science – volume: 12 year: 2021 ident: bib5 article-title: Understanding the secret of SARS-CoV-2 variants of concern/interest and immune escape publication-title: Front. Immunol. – volume: 149 start-page: 1242 year: 2022 end-page: 1252 e1212 ident: bib17 article-title: Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern publication-title: J. Allergy Clin. Immunol. – volume: 21 start-page: 346 year: 2009 end-page: 351 ident: bib8 article-title: Heterologous prime-boost vaccination publication-title: Curr. Opin. Immunol. – volume: 384 start-page: 1412 year: 2021 end-page: 1423 ident: bib21 article-title: BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting publication-title: N. Engl. J. Med. – volume: 600 start-page: 701 year: 2021 end-page: 706 ident: bib10 article-title: Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination publication-title: Nature – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: bib1 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: bib3 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. – volume: 384 start-page: 2092 year: 2021 end-page: 2101 ident: bib9 article-title: Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination publication-title: N. Engl. J. Med. – volume: 27 start-page: 1530 year: 2021 end-page: 1535 ident: bib29 article-title: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination publication-title: Nat. Med. – volume: 398 start-page: 121 year: 2021 end-page: 130 ident: bib30 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet – volume: 27 start-page: 2200322 year: 2022 ident: bib23 article-title: COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022 publication-title: Euro Surveill. – volume: 27 start-page: 1525 year: 2021 end-page: 1529 ident: bib27 article-title: Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination publication-title: Nat. Med. – volume: 34 start-page: 413 year: 2016 end-page: 423 ident: bib7 article-title: Prime-boost vaccine strategy against viral infections: mechanisms and benefits publication-title: Vaccine – volume: 94 start-page: 6529 year: 2022 end-page: 6539 ident: bib12 article-title: Antibody profiling in COVID-19 patients with different severities by using spike variant protein microarrays publication-title: Anal. Chem. – volume: 17 year: 2022 ident: bib33 article-title: Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico publication-title: PLoS One – volume: 385 start-page: 2413 year: 2021 end-page: 2420 ident: bib22 article-title: BNT162b2 vaccine booster and mortality due to Covid-19 publication-title: N. Engl. J. Med. – volume: 602 start-page: 657 year: 2022 end-page: 663 ident: bib24 article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies publication-title: Nature – volume: 584 start-page: 450 year: 2020 end-page: 456 ident: bib14 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature – volume: 12 start-page: 3788 year: 2022 ident: bib16 article-title: Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents publication-title: Sci. Rep. – volume: 387 start-page: 1011 year: 2022 end-page: 1020 ident: bib6 article-title: Covid-19 vaccines - immunity, variants, boosters publication-title: N. Engl. J. Med. – volume: 10 year: 2020 ident: bib36 article-title: A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots publication-title: Sci. Rep. – volume: 13 start-page: 3716 year: 2022 ident: bib32 article-title: Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies publication-title: Nat. Commun. – volume: 375 start-page: 1041 year: 2022 end-page: 1047 ident: bib28 article-title: Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination publication-title: Science – volume: 4 start-page: 129 year: 2021 ident: bib34 article-title: SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus publication-title: Commun. Biol. – volume: 93 start-page: 7690 year: 2021 end-page: 7698 ident: bib13 article-title: Development and application of human Coronavirus protein microarray for specificity analysis publication-title: Anal. Chem. – volume: 385 start-page: 1774 year: 2021 end-page: 1785 ident: bib2 article-title: Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase publication-title: N. Engl. J. Med. – volume: 14 year: 2022 ident: bib18 article-title: Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection publication-title: Sci. Transl. Med. – volume: 29 start-page: 819 year: 2021 end-page: 833.e817 ident: bib37 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe – volume: 38 start-page: 1073 year: 2020 end-page: 1078 ident: bib20 article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction publication-title: Nat. Biotechnol. – volume: 590 start-page: 375 year: 2021 end-page: 376 ident: bib39 article-title: Could mixing COVID vaccines boost immune response? publication-title: Nature – volume: 10 start-page: 1396 year: 2022 ident: bib26 article-title: Effectiveness of COVID-19 vaccine booster shot compared with Non-booster: a meta-analysis publication-title: Vaccines – volume: 11 year: 2021 ident: bib31 article-title: Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study publication-title: Lancet Reg. Health Eur. – volume: 184 start-page: 1171 year: 2021 end-page: 1187.e1120 ident: bib4 article-title: Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity publication-title: Cell – volume: 204 year: 2022 ident: bib11 article-title: Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects publication-title: Biosens. Bioelectron. – volume: 13 start-page: 4212 year: 2022 ident: bib38 article-title: Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR publication-title: Nat. Commun. – volume: 92 year: 2018 ident: bib35 article-title: Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome Coronavirus spike glycoprotein to avoid neutralization escape publication-title: J. Virol. – volume: 374 start-page: 1353 year: 2021 end-page: 1360 ident: bib15 article-title: Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant publication-title: Science – volume: 386 start-page: 1207 year: 2022 end-page: 1220 ident: bib40 article-title: Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection publication-title: N. Engl. J. Med. – volume: 7 start-page: 132 year: 2022 ident: bib41 article-title: SARS-CoV-2-specific CD4(+) T cells are associated with long-term persistence of neutralizing antibodies publication-title: Signal. Transduct Target Ther. – volume: 375 start-page: 678 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib19 article-title: Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science doi: 10.1126/science.abn7591 – volume: 600 start-page: 701 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib10 article-title: Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination publication-title: Nature doi: 10.1038/s41586-021-04120-y – volume: 384 start-page: 1412 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib21 article-title: BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2101765 – volume: 7 start-page: 132 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib41 article-title: SARS-CoV-2-specific CD4(+) T cells are associated with long-term persistence of neutralizing antibodies publication-title: Signal. Transduct Target Ther. doi: 10.1038/s41392-022-00978-0 – volume: 12 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib5 article-title: Understanding the secret of SARS-CoV-2 variants of concern/interest and immune escape publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.744242 – volume: 204 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib11 article-title: Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects publication-title: Biosens. Bioelectron. doi: 10.1016/j.bios.2022.114067 – volume: 12 start-page: 3788 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib16 article-title: Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents publication-title: Sci. Rep. doi: 10.1038/s41598-022-07849-2 – volume: 14 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib18 article-title: Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abn8057 – volume: 602 start-page: 671 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib25 article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization publication-title: Nature doi: 10.1038/s41586-021-04389-z – volume: 27 start-page: 1530 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib29 article-title: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination publication-title: Nat. Med. doi: 10.1038/s41591-021-01464-w – volume: 92 year: 2018 ident: 10.1016/j.mcpro.2023.100507_bib35 article-title: Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome Coronavirus spike glycoprotein to avoid neutralization escape publication-title: J. Virol. doi: 10.1128/JVI.02002-17 – volume: 584 start-page: 450 year: 2020 ident: 10.1016/j.mcpro.2023.100507_bib14 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature doi: 10.1038/s41586-020-2571-7 – volume: 13 start-page: 4212 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib38 article-title: Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR publication-title: Nat. Commun. doi: 10.1038/s41467-022-31796-1 – volume: 94 start-page: 6529 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib12 article-title: Antibody profiling in COVID-19 patients with different severities by using spike variant protein microarrays publication-title: Anal. Chem. doi: 10.1021/acs.analchem.1c05567 – volume: 34 start-page: 413 year: 2016 ident: 10.1016/j.mcpro.2023.100507_bib7 article-title: Prime-boost vaccine strategy against viral infections: mechanisms and benefits publication-title: Vaccine doi: 10.1016/j.vaccine.2015.11.062 – volume: 13 start-page: 3716 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib32 article-title: Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies publication-title: Nat. Commun. doi: 10.1038/s41467-022-31300-9 – volume: 385 start-page: 1774 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib2 article-title: Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2113017 – volume: 374 start-page: 1353 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib15 article-title: Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant publication-title: Science doi: 10.1126/science.abl9463 – volume: 27 start-page: 1525 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib27 article-title: Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination publication-title: Nat. Med. doi: 10.1038/s41591-021-01449-9 – volume: 184 start-page: 1171 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib4 article-title: Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity publication-title: Cell doi: 10.1016/j.cell.2021.01.037 – volume: 387 start-page: 1011 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib6 article-title: Covid-19 vaccines - immunity, variants, boosters publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra2206573 – volume: 27 start-page: 2200322 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib23 article-title: COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022 publication-title: Euro Surveill. doi: 10.2807/1560-7917.ES.2022.27.18.2200322 – volume: 149 start-page: 1242 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib17 article-title: Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2022.01.013 – volume: 29 start-page: 819 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib37 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.005 – volume: 386 start-page: 1207 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib40 article-title: Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2118691 – volume: 10 year: 2020 ident: 10.1016/j.mcpro.2023.100507_bib36 article-title: A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots publication-title: Sci. Rep. doi: 10.1038/s41598-020-76913-6 – volume: 590 start-page: 375 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib39 article-title: Could mixing COVID vaccines boost immune response? publication-title: Nature doi: 10.1038/d41586-021-00315-5 – volume: 602 start-page: 657 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib24 article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies publication-title: Nature doi: 10.1038/s41586-021-04385-3 – volume: 17 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib33 article-title: Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico publication-title: PLoS One doi: 10.1371/journal.pone.0269032 – volume: 38 start-page: 1073 year: 2020 ident: 10.1016/j.mcpro.2023.100507_bib20 article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction publication-title: Nat. Biotechnol. doi: 10.1038/s41587-020-0631-z – volume: 4 start-page: 129 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib34 article-title: SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus publication-title: Commun. Biol. doi: 10.1038/s42003-021-01649-6 – volume: 375 start-page: 1041 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib28 article-title: Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination publication-title: Science doi: 10.1126/science.abn2688 – volume: 11 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib31 article-title: Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study publication-title: Lancet Reg. Health Eur. – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.mcpro.2023.100507_bib3 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – volume: 384 start-page: 2092 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib9 article-title: Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2104840 – volume: 93 start-page: 7690 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib13 article-title: Development and application of human Coronavirus protein microarray for specificity analysis publication-title: Anal. Chem. doi: 10.1021/acs.analchem.1c00614 – volume: 397 start-page: 99 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib1 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – volume: 10 start-page: 1396 year: 2022 ident: 10.1016/j.mcpro.2023.100507_bib26 article-title: Effectiveness of COVID-19 vaccine booster shot compared with Non-booster: a meta-analysis publication-title: Vaccines doi: 10.3390/vaccines10091396 – volume: 21 start-page: 346 year: 2009 ident: 10.1016/j.mcpro.2023.100507_bib8 article-title: Heterologous prime-boost vaccination publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2009.05.016 – volume: 385 start-page: 2413 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib22 article-title: BNT162b2 vaccine booster and mortality due to Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2115624 – volume: 398 start-page: 121 year: 2021 ident: 10.1016/j.mcpro.2023.100507_bib30 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)01420-3 |
| SSID | ssj0020175 |
| Score | 2.4525115 |
| Snippet | In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Owing to the ongoing mutations, especially for the variants of concern... In November 2022, 68% of the population received at least one dose of COVID-19 vaccines. Due to the ongoing mutations, especially for the variants of concern... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 100507 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 Antibodies, Neutralizing ChAdOx1 nCoV-19 COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Humans Immunity, Humoral mix-and-match Protein Array Analysis protein microarray SARS-CoV-2 SARS-CoV-2 variants vaccine |
| Title | Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays |
| URI | https://dx.doi.org/10.1016/j.mcpro.2023.100507 https://www.ncbi.nlm.nih.gov/pubmed/36787877 https://www.proquest.com/docview/2777011501 https://pubmed.ncbi.nlm.nih.gov/PMC9922205 |
| Volume | 22 |
| WOSCitedRecordID | wos001003128700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Open Access: DOAJ - Directory of Open Access Journals customDbUrl: eissn: 1535-9484 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020175 issn: 1535-9476 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFBZZt8Fextbukl2KBmMvmUoiX_WYpB0ZpW1oupI3YzsydUmcEtsh-bv7JTu6uU7CyjYYAZPIlmPrfJY_Sed8B6HPEXBgn0XQ-1GLExveOSQKI0ao63EauX6cxBOZbMI7P_fHYzZsNH6aWJjl1Msyf7Vid__V1FAGxhahs39h7uqkUADfweiwBbPD9o8MP5RZuMUMwE05k_H3qYwBAbatEoLP0pWJTAS6qnwp-xfX349Jh7WWYSyW2vNWKScRRt3LEenPrwmFPXDxWdGSyg5pBqeBPjxcLMJ1Xme4ZybfrgSVWBeQP2QtEQFdWzySs7SDOZERDlvFpyWUwZ4Kd8elJLxpRsY1RJ_yXOcT64VFCedp9VLlwVLNZVCr5gIjo-EGJy2w1eDicnRUhQVIHl6F30CvKVZRhIbBNJFk3Sxs1b1ce6lIN6by5SmHlereVYrP9UaX7xBme1qQu16mktftvGTUfMft0SyGtjsS9yF8TRyVvXdLvXt41hfKv1TI7D6mnsOYGfbrSQHoER2l6auuwihjSR_EnX_4HXvaHR1tO_nWWNPVC_RcD3dwV8H0JWrwbB8ddLOwmM_W-AuWDsiyqfbRU91oByivMIw1hrHBMJYYxgrDGBodGwxjg2FsMIwlhvE9hrHGMNYYxjUMv0I_vp1c9QdEZwchse2wgvDYYq7PJ1bo-U7kMt-OqAtk12tzh1pWAsx40k4moc9duxOKYTrjnXYSwZghtPw2t16jvWye8bcIR5FgsgkVWuN2BAfCaw3qWizsxNTntImoafUg1tL5IoPLNDA-kreBNFUgTBUoUzXR16rSnVKOefhw15gz0ORXkdoAYPdwxU_G-AEgXjzXYcbnZR5Qz_PkiK_TRG8UGKorsYCkwgdqexswqQ4QsvObe7L0RsrPazy_--ea79Gz-4f_A9orFiX_iJ7EyyLNF4fokTf2D-VD8gvfkQQf |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Profiling+humoral+immunity+after+mixing+and+matching+COVID-19+vaccines+using+SARS-CoV-2+variant+protein+microarrays&rft.jtitle=Molecular+%26+cellular+proteomics&rft.au=Kuo%2C+Ho-Chang&rft.au=Kuo%2C+Kuang-Che&rft.au=Du%2C+Pin-Xian&rft.au=Keskin%2C+Batuhan+Birol&rft.date=2023-04-01&rft.pub=THE+AUTHORS.+Published+by+Elsevier+Inc+on+behalf+of+American+Society+for+Biochemistry+and+Molecular+Biology&rft.issn=1535-9476&rft.eissn=1535-9484&rft_id=info:doi/10.1016%2Fj.mcpro.2023.100507&rft.externalDocID=PMC9922205 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-9476&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-9476&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-9476&client=summon |